drugset / Trial / NCT00381212
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
Phase 1/2
Completed
10 enrolled
McGill University Health Centre/Research Institute of the McGill University Health Centre
Argos Therapeutics · collabUniversité de Montréal · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To Investigate the safety and immunologic activity of AGS-004, an autologous HIV Immunotherapeutic, in HIV-infected adults currently on stable antiretroviral therapy (ART) with durable viral suppression.
Timeline
- Start
- 2006-09
- Primary completion
- 2008-02
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGS-004 | Cell therapy | — | Other |